FierceBiotech14h
Corbus posts first US data on challenger to Pfizer’s ADC Padcev
Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...
Corbus Pharmaceuticals falls after trial data for lead asset
Corbus Pharmaceuticals (CRBP) stock drops 12% after mixed Phase 1 trial results for its lead cancer candidate. Read more here.
Corbus Pharmaceuticals announces data from its US, UK study of CRB-701
Corbus Pharmaceuticals (CRBP) announced that data from its US and UK conducted first-in-human dose escalation clinical study of CRB-701 is ...
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors
Shares of Corbus Pharmaceuticals Holdings Inc. CRBP tumbled 10.23% to $8.51 Friday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index COMP ...
RBC Capital Sticks to Its Buy Rating for Corbus Pharmaceuticals (CRBP)
In a report released on February 11, Brian Abrahams from RBC Capital maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research ...
STAT15h
Corbus reports first Western data for closely tracked ADC cancer drug
Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.
Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate
Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.
STAT13h
The view from overseas on tumult in U.S. science
Happy V-Day! Gorge on heart-shaped chocolate and ponder the implications of RFK Jr. being sworn in as health secretary. Today, we talk about that, as well as new cancer data from Corbus Pharma, Europe ...